• ATRA Overcomes Platinum-Induced PARP Resistance in EOC

  2026-08-29

  This study shows that cisplatin exposure can create a PARP inhibitor-resistant state in epithelial ovarian cancer, while subsequent all-trans retinoic acid treatment suppresses that state through coordinated effects on NAD+ metabolism and resistance-associated proteins. The findings support a sequential cisplatin–ATRA–niraparib maintenance strategy, although validation in clinically representative and molecularly stratified models remains necessary.

• LY2109761: TGF-β Signaling Workflow Guide

  2026-08-28

  LY2109761 enables controlled interrogation of TβRI/II-dependent signaling in cancer, stem-cell plasticity, radiosensitization, and fibrosis models. This guide emphasizes assay design, time-resolved Smad readouts, formulation control, and troubleshooting rather than treating pathway inhibition as a one-size-fits-all intervention.

• Recombinant Mouse SHH: From Morphogen to Model

  2026-08-28

  A translational perspective on how recombinant Sonic Hedgehog can clarify species-specific embryonic patterning, strengthen developmental assays, and inform congenital malformation research without overstating what experimental models can predict.

• Necrostatin-1 for RIP1 Kinase Necroptosis Assays

  2026-08-27

  Necrostatin-1 provides a practical pharmacological checkpoint for testing whether RIP1 kinase drives inflammatory cell death, tissue injury, or differentiation defects. This guide translates its use from controlled cell assays into bone, liver, and acute kidney injury research while emphasizing solvent control, orthogonal readouts, and reproducible workflow design.

• Lysosomal β-Galactosidase Staining Kit Guide

  2026-08-27

  Learn how Lysosomal β-Galactosidase Staining Kit K2181 supports reproducible lysosomal enzyme visualization in cell senescence and chemoresistance workflows. The article distinguishes lysosomal acidic β-galactosidase from senescence-specific and bacterial β-galactosidase while providing practical guidance on controls, compatibility, interpretation, and vendor selection.

• 2-Hydroxypropyl-β-cyclodextrin Protocol Guide

  2026-08-26

  2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide solubilizer for screening poorly water-soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. It is appropriate for pharmaceutical solubility improvement, biochemical formulation work, and use as a drug formulation excipient, but the available dossier does not establish therapeutic efficacy, clinical bioavailability, or broader applications.

• GI 254023X: ADAM10 Inhibitor Workflows

  2026-08-26

  GI 254023X enables selective interrogation of ADAM10 sheddase activity in Jurkat signaling and endothelial barrier models. This practical guide connects exposure control, orthogonal readouts, toxin-challenge workflows, and troubleshooting to help researchers distinguish target engagement from nonspecific cytotoxicity.

• Pollen Interference in Hazardous Substance Fluorescence

  2026-08-25

  The reference study develops a spectral preprocessing and random-forest workflow that reduces pollen interference in excitation–emission matrix fluorescence classification of hazardous bioaerosol components. Its strongest practical contribution is showing that feature transformation, particularly fast Fourier transform processing, can improve discrimination of bacterial and toxin-related signatures without treating pollen as an irrelevant nuisance variable.

• Necrostatin-1: RIP1 Signaling Beyond Cell Death

  2026-08-25

  Necrostatin-1 is a selective RIP1 kinase inhibitor for resolving whether cellular injury involves kinase-dependent necroptosis or redox-driven metabolic collapse. This article translates recent osteosarcoma vitamin C findings into a rigorous, mechanism-first assay strategy.

• HEY2 Biology Meets T7 RNA Polymerase

  2026-08-24

  The HEY2–HDAC1 regulatory module links cardiac energy failure to transcriptional control. This thought-leadership article explains how T7 RNA Polymerase can help translational researchers convert such mechanistic insights into controlled RNA-based experiments while clarifying the boundaries between platform utility and therapeutic evidence.

• NVP-BGJ398 Phosphate: FGFR Research Guide

  2026-08-24

  NVP-BGJ398 phosphate is a potent FGFR1–3 inhibitor for studying altered FGFR signaling in cancer and skeletal disease models. Supplier-reported biochemical IC50 values are 0.9 nM for FGFR1, 1.4 nM for FGFR2, and 1 nM for FGFR3, while peer-reviewed mouse data support pharmacological inhibition of FGFR3 signaling in SLC26A2-related chondrodysplasia.

• C8-HSL: From Quorum Sensing to Cancer Biology

  2026-08-23

  N-octanoyl-L-Homoserine lactone is evolving from a quorum-sensing reagent into a translational probe for connecting bacterial communication with host-cell signaling. This thought-leadership guide examines the PI3K/AKT/ERK evidence, proposes validation workflows, and outlines responsible paths toward infection biology and cancer–microbiota research.

• Temafloxacin Activity Against Gram-Positive Bacteria

  2026-08-22

  The reference study combined new broth-microdilution data with a literature review to define temafloxacin’s enhanced in-vitro activity against clinically important Gram-positive cocci. Its findings support strong activity against Staphylococcus aureus and Streptococcus pneumoniae while also showing how pH, serum, magnesium, urine, and inoculum conditions can affect interpretation.

• GSK 2837808A: LDHA Inhibition Workflow

  2026-08-22

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor for dissecting lactate production, glucose consumption, and tumor–immune signaling. This workflow translates its biochemical selectivity into practical cell-based assays for cancer metabolism research while addressing exposure, solubility, and pathway-specific interpretation.

• MRT68921: Turning Autophagy Off to See It Clearly

  2026-08-21

  Autophagy research is moving from descriptive imaging toward causal pathway analysis. This thought-leadership article explains how MRT68921, a dual ULK1/2 inhibitor, can help translational researchers connect ULK signaling with lipid metabolism, ATG13 phosphorylation, and LC3 flux while maintaining appropriate preclinical boundaries.

7862 records 1/525 page Next 12345 下5页 Last page